Aclaris Q1 net loss widens to $19.8M; positive Phase 1a data for ATI-052

Aclaris Therapeutics, Inc.

2026-Q1 EPS reported -$0.15 revenue$1,996,000

Net loss $19.8M vs $15.1M YoY; revenue $2.0M (+33%) on higher Lilly/Sun Pharma royalties.
Cash & equivalents $190.8M (up from $151.4M); raised $59.8M via 18.4M share ATM offering in March.
ATI-052 Phase 1a SAD/MAD showed half-life ~45 days, sustained target engagement up to 20 wks; supports Q3-month dosing.
Phase 1b POC trials in asthma and atopic dermatitis ongoing; top line results expected H2 2026.
Completed enrollment in bosakitug Phase 2 AD trial; results expected Q4 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aclaris Therapeutics, Inc. reported first quarter of 2026 results: revenue $2.0 million, net income Net loss was $19.8 million.

Period: first quarter of 2026
Revenue: $2.0 million
Net income: Net loss was $19.8 million
Result: reported results

Exact text from the filing

First quarter 2026 Net loss was $19.8 million for the first quarter of 2026 compared to $15.1 million for the first quarter of 2025. Total revenue was $2.0 million for the first quarter of 2026 compared to $1.5 million for the first quarter of 2025.

View on SEC.gov

Browse all earnings releases →

Aclaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-056669

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.